Relay Therapeutics, Inc. (RLAY) financial statements and ratios from SEC XBRL: revenue $15.36M (TTM), net margin -1800.6%, revenue growth 53.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $15.36M |
| Net Margin | -1800.6% |
| Revenue Growth (YoY) | 53.4% |
| EPS Growth (YoY) | -31.8% |
| FCF Growth (YoY) | -6.1% |
| Price / Book | 5.88 |
| Price / Sales | 332.44 |
| FCF Yield | -10.4% |
| Altman Z-Score | 33.88 (safe) |
| Sector P/E (Healthcare) | 21.6 |
RLAY overview · RLAY earnings · RLAY KPIs · RLAY investor relations · RLAY ownership · RLAY peers · RLAY filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.